Access to durvalumab for lung cancer is cost-prohibitive

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A new study examines the cost-effectiveness of durvalumab, a targeted immunotherapy for lung cancer that is known to extend lifespan. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login